The association between young age atmetastatic breast cancer diagnosis andoverall survival in the EMBRACE study Por Kati The association between young age atmetastatic breast cancer diagnosis andoverall survival in the EMBRACE study Read More »
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity Por Kati GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity Read More »
Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer Por Adson Machado Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer Read More »
Iodine Seed−Marking Protocol for Response-Guided Axillary TreatmentAfter Systemic Therapy for Node-Positive Breast Cancer Por Adson Machado Iodine Seed−Marking Protocol for Response-Guided Axillary TreatmentAfter Systemic Therapy for Node-Positive Breast Cancer Read More »
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay Por Adson Machado Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay Read More »
Biology is Queen: The Oncotype DX 21‑Gene Recurrence ScoreHas Stronger Prognostic Ability than Lymph Node Burdenfor Patients with Breast Cancer Por Adson Machado Biology is Queen: The Oncotype DX 21‑Gene Recurrence ScoreHas Stronger Prognostic Ability than Lymph Node Burdenfor Patients with Breast Cancer Read More »
Patritumab deruxtecan in HR+HER2−advanced breast cancer: a phase 2 trial Por Kati Patritumab deruxtecan in HR+HER2−advanced breast cancer: a phase 2 trial Read More »
Axillary dissection is avoidable in most cT1N0 triple‑negative & HER2+breast cancers treated with upfront surgery Por Kati Axillary dissection is avoidable in most cT1N0 triple‑negative & HER2+breast cancers treated with upfront surgery Read More »
A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risktriple-negative early breast cancer patients Por Kati A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risktriple-negative early breast cancer patients Read More »
Axillary surgery in early breast cancer: real-world analysis of theINSEMA-trial at three certified university breast cancer centers in Germanyregarding the omission of sentinel lymph node biopsy Por Kati Axillary surgery in early breast cancer: real-world analysis of theINSEMA-trial at three certified university breast cancer centers in Germanyregarding the omission of sentinel lymph node biopsy Read More »
Impact of a Weight Loss Intervention on 1-Year Weight Changein Women With Stage II/III Breast Cancer Por Kati Impact of a Weight Loss Intervention on 1-Year Weight Changein Women With Stage II/III Breast Cancer Read More »
The impact of radiotherapy on trials of axillary management in early breastcancer Por Kati The impact of radiotherapy on trials of axillary management in early breastcancer Read More »
